Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
Clinical trial NCT06549465 · RECRUITING
Trial details
- NCT number
- NCT06549465
- Sponsor
- Convergent Therapeutics
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-06
- Primary completion
- 2027-04-20
- Enrollment
- 93
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.